{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:34:39Z","timestamp":1794962079999,"version":"4.9.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j intensive care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Severe community-acquired pneumonia represents the most critical manifestation of pneumonia acquired outside the hospital and remains a major cause of intensive care admission and death worldwide. It is frequently complicated by acute respiratory failure, circulatory shock, and multiple organ dysfunction, with mortality commonly exceeding 25\u201340%. Despite progress in vaccination programmes, microbiological diagnostics, and critical care support, major uncertainties persist regarding early recognition, pathogen identification, antimicrobial selection and duration, management of co-infections, and assessment of treatment response. These challenges are amplified by increasing host heterogeneity and antimicrobial resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>Contemporary epidemiological studies consistently demonstrate that mortality in severe community\u2013acquired pneumonia is closely linked to the severity of organ dysfunction rather than to pulmonary involvement alone. In response, the recent international guideline definitions incorporate both respiratory and systemic criteria to standardise identification and guide early triage. However, these frameworks also reveal substantial variability related to host factors that influence clinical presentation, microbiological findings, and outcomes. Advanced age, sex, chronic cardiopulmonary disease, diabetes, frailty, and prior healthcare exposure modify risk, while immunocompromised populations\u2014including transplant recipients, patients with malignancy, individuals receiving immunomodulatory therapies, and people living with Human Immunodeficiency Virus in resource-limited settings\u2014face distinct diagnostic and therapeutic challenges.<\/jats:p>\n                    <jats:p>Accurate microbiological diagnosis remains difficult, with mixed or unidentified infections frequently encountered. Structured respiratory sampling and molecular diagnostic techniques, particularly lower respiratory tract multiplex polymerase chain reaction panels, have improved pathogen detection and support earlier optimisation of antimicrobial therapy. Biomarkers such as procalcitonin and C-reactive protein provide complementary information on disease trajectory and response to treatment, enabling more confident reassessment and earlier discontinuation of antibiotics when aligned with clinical improvement. Severity stratification using combined clinical scores, radiological extent, and laboratory markers refines prognostication and informs treatment intensity. Empiric antimicrobial therapy should be initiated promptly and individualised according to patient-specific risk factors for resistant pathogens, with systematic reassessment within 24\u201348\u00a0h. Adjunctive strategies, including advanced respiratory and haemodynamic support, corticosteroids in selected inflammatory phenotypes, and emerging host-directed therapies such as intravenous immunoglobulins, form part of a personalised management approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An integrated, multidisciplinary strategy that links early recognition, diagnostic precision, severity assessment, and personalised therapy offers a coherent pathway to improve outcomes and promote responsible antimicrobial use in severe community-acquired pneumonia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40560-026-00854-x","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:35:33Z","timestamp":1769844933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Severe community-acquired pneumonia: an integral approach"],"prefix":"10.1186","volume":"14","author":[{"given":"Arsah","family":"Asis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Fujitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Povoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Felipe","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Martin-Loeches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"854_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241311038","author":"R Anderson","year":"2023","unstructured":"Anderson R, Feldman C. The global burden of community-acquired pneumonia in adults, encompassing invasive pneumococcal disease and the prevalence of its associated cardiovascular events, with a focus on pneumolysin and macrolide antibiotics in pathogenesis and therapy. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241311038.","journal-title":"Int J Mol Sci"},{"issue":"10517","key":"854_CR2","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1016\/S0140-6736(25)01493-X","volume":"406","author":"LF Reyes","year":"2025","unstructured":"Reyes LF, Conway Morris A, Serrano-Mayorga C, et al. Community-acquired pneumonia. Lancet. 2025;406(10517):2371\u201388.","journal-title":"Lancet"},{"issue":"2","key":"854_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00134-019-05519-y","volume":"45","author":"A Torres","year":"2019","unstructured":"Torres A, Chalmers JD, Dela Cruz CS, et al. Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med. 2019;45(2):159\u201371.","journal-title":"Intensive Care Med"},{"issue":"7","key":"854_CR4","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the american thoracic society and infectious diseases society of america. Am J Respir Crit Care Med. 2019;200(7):e45\u201367.","journal-title":"Am J Respir Crit Care Med"},{"key":"854_CR5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00735-2022","author":"I Martin-Loeches","year":"2023","unstructured":"Martin-Loeches I, Torres A, Nagavci B, et al. ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia. Eur Respir J. 2023. https:\/\/doi.org\/10.1183\/13993003.00735-2022.","journal-title":"Eur Respir J"},{"issue":"1","key":"854_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/2110-5820-2-32","volume":"2","author":"P P\u00f3voa","year":"2012","unstructured":"P\u00f3voa P, Salluh JI. Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review. Ann Intensive Care. 2012;2(1):32.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"854_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1465-9921-15-75","volume":"15","author":"I Martin-Loeches","year":"2014","unstructured":"Martin-Loeches I, Valles X, Menendez R, et al. Predicting treatment failure in patients with community acquired pneumonia: a case-control study. Respir Res. 2014;15(1):75.","journal-title":"Respir Res"},{"issue":"5","key":"854_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/thorax.58.5.377","volume":"58","author":"WS Lim","year":"2003","unstructured":"Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377\u201382.","journal-title":"Thorax"},{"issue":"12","key":"854_CR9","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1086\/498119","volume":"41","author":"M Bod\u00ed","year":"2005","unstructured":"Bod\u00ed M, Rodr\u00edguez A, Sol\u00e9-Viol\u00e1n J, et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis. 2005;41(12):1709\u201316.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"854_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/QCO.0000000000000819","volume":"35","author":"I Martin-Loeches","year":"2022","unstructured":"Martin-Loeches I, Garduno A, Povoa P, et al. Choosing antibiotic therapy for severe community-acquired pneumonia. Curr Opin Infect Dis. 2022;35(2):133\u20139.","journal-title":"Curr Opin Infect Dis"},{"issue":"4","key":"854_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJM199701233360402","volume":"336","author":"MJ Fine","year":"1997","unstructured":"Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243\u201350.","journal-title":"N Engl J Med"},{"issue":"6","key":"854_CR12","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1183\/09031936.06.00139305","volume":"27","author":"J Rello","year":"2006","unstructured":"Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J. 2006;27(6):1210\u20136.","journal-title":"Eur Respir J"},{"issue":"Suppl 4","key":"854_CR13","first-page":"Iv1","volume":"56","author":"British Thoracic Society Standards of Care Committee","year":"2001","unstructured":"British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax. 2001;56(Suppl 4):Iv1-64.","journal-title":"Thorax"},{"issue":"1","key":"854_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191721","volume":"13","author":"M Ferrer","year":"2018","unstructured":"Ferrer M, Travierso C, Cilloniz C, et al. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients. PLoS ONE. 2018;13(1):e0191721.","journal-title":"PLoS ONE"},{"issue":"9","key":"854_CR15","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S1473-3099(24)00176-2","volume":"24","author":"RG Bender","year":"2024","unstructured":"Bender RG, Sirota SB, Swetschinski LR, et al. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990\u20132021: a systematic analysis from the global burden of disease study 2021. Lancet Infect Dis. 2024;24(9):974\u20131002.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"854_CR16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1500245","volume":"373","author":"S Jain","year":"2015","unstructured":"Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med. 2015;373(5):415\u201327.","journal-title":"N Engl J Med"},{"issue":"Suppl 2(Suppl 2","key":"854_CR17","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"LA Mandell","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America\/American Thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2(Suppl 2)):S27-72.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"854_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.arbres.2022.08.012","volume":"59","author":"C Cilloniz","year":"2023","unstructured":"Cilloniz C, Ferrer M, Peric\u00e0s JM, et al. Validation of IDSA\/ATS guidelines for ICU admission in adults over 80 years old with community-acquired pneumonia. Arch Bronconeumol. 2023;59(1):19\u201326.","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"854_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1473-3099(17)30592-3","volume":"18","author":"P Schuetz","year":"2018","unstructured":"Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95\u2013107.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"854_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1183\/09031936.03.00057302","volume":"21","author":"PP Espa\u00f1a","year":"2003","unstructured":"Espa\u00f1a PP, Capelastegui A, Quintana JM, et al. A prediction rule to identify allocation of inpatient care in community-acquired pneumonia. Eur Respir J. 2003;21(4):695\u2013701.","journal-title":"Eur Respir J"},{"issue":"3","key":"854_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1086\/589754","volume":"47","author":"PG Charles","year":"2008","unstructured":"Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47(3):375\u201384.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"854_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"issue":"10","key":"854_CR23","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1164\/rccm.201611-2262OC","volume":"196","author":"OT Ranzani","year":"2017","unstructured":"Ranzani OT, Prina E, Men\u00e9ndez R, et al. New sepsis definition (Sepsis-3) and community-acquired pneumonia mortality. A validation and clinical decision-making study. Am J Respir Crit Care Med. 2017;196(10):1287\u201397.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"854_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1183\/13993003.00191-2016","volume":"48","author":"A Liapikou","year":"2016","unstructured":"Liapikou A, Cill\u00f3niz C, Gabarr\u00fas A, et al. Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia. Eur Respir J. 2016;48(1):257\u201361.","journal-title":"Eur Respir J"},{"key":"854_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108014","volume":"240","author":"AE Vi\u00f1\u00e1n Garc\u00e9s","year":"2025","unstructured":"Vi\u00f1\u00e1n Garc\u00e9s AE, Sanabria-Herrera N, Duque S, et al. Severe community-acquired pneumonia in immunosuppressed patients admitted to the ICU. Respir Med. 2025;240:108014.","journal-title":"Respir Med"},{"issue":"1","key":"854_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00134-016-4578-y","volume":"43","author":"I Martin-Loeches","year":"2017","unstructured":"Martin-Loeches I, M JS, Vincent JL, et al. Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Med. 2017;43(1):48\u201358.","journal-title":"Intensive Care Med"},{"issue":"1","key":"854_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/thx.2009.129502","volume":"67","author":"T Welte","year":"2012","unstructured":"Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71\u20139.","journal-title":"Thorax"},{"issue":"4","key":"854_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1086\/499955","volume":"42","author":"AR Falsey","year":"2006","unstructured":"Falsey AR, Walsh EE. Viral pneumonia in older adults. Clin Infect Dis. 2006;42(4):518\u201324.","journal-title":"Clin Infect Dis"},{"issue":"17","key":"854_CR29","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1056\/NEJMra1312885","volume":"371","author":"DM Musher","year":"2014","unstructured":"Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014;371(17):1619\u201328.","journal-title":"N Engl J Med"},{"issue":"6","key":"854_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/cid\/ciy874","volume":"68","author":"TM Uyeki","year":"2019","unstructured":"Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the infectious diseases society of america: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis. 2019;68(6):895\u2013902.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"854_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-025-05623-0","volume":"29","author":"Y de Albuquerque Pessoa Dos Santos","year":"2025","unstructured":"de Albuquerque Pessoa Dos Santos Y, Tomazini BM, Dos Santos MHC, et al. Impact of syndromic molecular diagnostics on antimicrobial adequacy and time to therapy in critically ill patients with pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care. 2025;29(1):379.","journal-title":"Crit Care"},{"issue":"10","key":"854_CR32","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/cid\/ciw494","volume":"63","author":"KE Hanson","year":"2016","unstructured":"Hanson KE, Couturier MR. Multiplexed molecular diagnostics for respiratory, gastrointestinal, and central nervous system infections. Clin Infect Dis. 2016;63(10):1361\u20137.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"854_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s00134-019-05520-5","volume":"45","author":"JF Timsit","year":"2019","unstructured":"Timsit JF, Bassetti M, Cremer O, et al. Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive Care Med. 2019;45(2):172\u201389.","journal-title":"Intensive Care Med"},{"issue":"2","key":"854_CR34","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00134-024-07772-2","volume":"51","author":"VI Enne","year":"2025","unstructured":"Enne VI, Stirling S, Barber JA, et al. INHALE WP3, a multicentre, open-label, pragmatic randomised controlled trial assessing the impact of rapid, ICU-based, syndromic PCR, versus standard-of-care on antibiotic stewardship and clinical outcomes in hospital-acquired and ventilator-associated pneumonia. Intensive Care Med. 2025;51(2):272\u201386.","journal-title":"Intensive Care Med"},{"issue":"1","key":"854_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13613-024-01323-0","volume":"14","author":"P P\u00f3voa","year":"2024","unstructured":"P\u00f3voa P, Coelho L, Cidade JP, et al. Biomarkers in pulmonary infections: a clinical approach. Ann Intensive Care. 2024;14(1):113.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"854_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04677-2","volume":"27","author":"M Papp","year":"2023","unstructured":"Papp M, Kiss N, Baka M, et al. Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival-a systematic review and meta\u2014analysis. Crit Care. 2023;27(1):394.","journal-title":"Crit Care"},{"issue":"1","key":"854_CR37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12879-023-08255-3","volume":"23","author":"RF Dias","year":"2023","unstructured":"Dias RF, de Paula A, Hasparyk UG, et al. Use of C-reactive protein to guide the antibiotic therapy in hospitalized patients: a systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):276.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"854_CR38","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1164\/rccm.201709-1908OC","volume":"198","author":"R M\u00e9ndez","year":"2018","unstructured":"M\u00e9ndez R, Men\u00e9ndez R, Cill\u00f3niz C, et al. Initial inflammatory profile in community-acquired pneumonia depends on time since onset of symptoms. Am J Respir Crit Care Med. 2018;198(3):370\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"854_CR39","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2024.26458","volume":"333","author":"P Dark","year":"2025","unstructured":"Dark P, Hossain A, McAuley DF, et al. Biomarker-guided antibiotic duration for hospitalized patients with suspected sepsis: the adapt-sepsis randomized clinical trial. JAMA. 2025;333(8):682\u201393.","journal-title":"JAMA"},{"issue":"9","key":"854_CR40","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1097\/CCM.0b013e31821e8791","volume":"39","author":"JU Jensen","year":"2011","unstructured":"Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011;39(9):2048\u201358.","journal-title":"Crit Care Med"},{"key":"854_CR41","unstructured":"Jones BE, Ramirez JA, Oren E, et al. 2025 Diagnosis and Management of Community-acquired Pneumonia. An Official American thoracic society clinical practice guideline. Am J Respir Crit Care Med."},{"issue":"9","key":"854_CR42","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1007\/s00134-025-08034-5","volume":"51","author":"S Keane","year":"2025","unstructured":"Keane S, Leone M, Martin-Loeches I. Penicillin allergy assessment and testing: worth the risk in critically ill patients. Intensive Care Med. 2025;51(9):1714\u20136.","journal-title":"Intensive Care Med"},{"issue":"3","key":"854_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2018","unstructured":"Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285\u201395.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"854_CR44","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","volume":"19","author":"MH Kollef","year":"2019","unstructured":"Kollef MH, Nov\u00e1\u010dek M, Kivistik \u00dc, et al. Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19(12):1299\u2013311.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"854_CR45","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/ja.2016.137","volume":"70","author":"P Fernandes","year":"2017","unstructured":"Fernandes P, Martens E, Pereira D. Nature nurtures the design of new semi-synthetic macrolide antibiotics. J Antibiot (Tokyo). 2017;70(5):527\u201333.","journal-title":"J Antibiot (Tokyo)"},{"key":"854_CR46","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1183\/16000617.0117-2023","volume":"32","author":"A Torres","year":"2023","unstructured":"Torres A, Kuraieva A, Stone GG, et al. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia. Eur Respir Rev. 2023;32:170.","journal-title":"Eur Respir Rev"},{"key":"854_CR47","first-page":"4565","volume":"9","author":"A Liapikou","year":"2015","unstructured":"Liapikou A, Cill\u00f3niz C, Torres A. Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Des Devel Ther. 2015;9:4565\u201372.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"854_CR48","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12890-021-01472-z","volume":"21","author":"TM File Jr","year":"2021","unstructured":"File TM Jr, Alexander E, Goldberg L, et al. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities. BMC Pulm Med. 2021;21(1):154.","journal-title":"BMC Pulm Med"},{"issue":"6","key":"854_CR49","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517\u201327.","journal-title":"N Engl J Med"},{"issue":"5 Pt 2","key":"854_CR50","first-page":"H1440","volume":"259","author":"C Natanson","year":"1990","unstructured":"Natanson C, Danner RL, Reilly JM, et al. Antibiotics versus cardiovascular support in a canine model of human septic shock. Am J Physiol. 1990;259(5 Pt 2):H1440\u20137.","journal-title":"Am J Physiol"},{"issue":"9","key":"854_CR51","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1711584","volume":"378","author":"MW Semler","year":"2018","unstructured":"Semler MW, Self WH, Wanderer JP, et al. Balanced crystalloids versus saline in critically ill adults. N Engl J Med. 2018;378(9):829\u201339.","journal-title":"N Engl J Med"},{"issue":"11","key":"854_CR52","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063\u2013143.","journal-title":"Crit Care Med"},{"issue":"10","key":"854_CR53","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1007\/s00134-014-3367-8","volume":"40","author":"A Vieillard-Baron","year":"2014","unstructured":"Vieillard-Baron A, Cecconi M. Understanding cardiac failure in sepsis. Intensive Care Med. 2014;40(10):1560\u20133.","journal-title":"Intensive Care Med"},{"issue":"1","key":"854_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40560-015-0084-5","volume":"3","author":"M Nishimura","year":"2015","unstructured":"Nishimura M. High-flow nasal cannula oxygen therapy in adults. J Intensive Care. 2015;3(1):15.","journal-title":"J Intensive Care"},{"issue":"11","key":"854_CR55","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1164\/rccm.201803-0589OC","volume":"199","author":"O Roca","year":"2019","unstructured":"Roca O, Caralt B, Messika J, et al. An Index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019;199(11):1368\u201376.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"854_CR56","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1164\/rccm.201605-0916OC","volume":"195","author":"T Mauri","year":"2017","unstructured":"Mauri T, Turrini C, Eronia N, et al. Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2017;195(9):1207\u201315.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"854_CR57","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1007\/s00134-011-2354-6","volume":"37","author":"B Sztrymf","year":"2011","unstructured":"Sztrymf B, Messika J, Bertrand F, et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. Intensive Care Med. 2011;37(11):1780\u20136.","journal-title":"Intensive Care Med"},{"issue":"23","key":"854_CR58","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1056\/NEJMoa1503326","volume":"372","author":"JP Frat","year":"2015","unstructured":"Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185\u201396.","journal-title":"N Engl J Med"},{"key":"854_CR59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1183\/13993003.02426-2016","volume":"50","author":"B Rochwerg","year":"2017","unstructured":"Rochwerg B, Brochard L, Elliott MW, et al. Official ERS\/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50:2.","journal-title":"Eur Respir J"},{"key":"854_CR60","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jcrc.2020.08.018","volume":"61","author":"J Weatherald","year":"2021","unstructured":"Weatherald J, Solverson K, Zuege DJ, et al. Awake prone positioning for COVID-19 hypoxemic respiratory failure: a rapid review. J Crit Care. 2021;61:63\u201370.","journal-title":"J Crit Care"},{"issue":"12","key":"854_CR61","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S2213-2600(21)00356-8","volume":"9","author":"S Ehrmann","year":"2021","unstructured":"Ehrmann S, Li J, Ibarra-Estrada M, et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med. 2021;9(12):1387\u201395.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"854_CR62","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00134-025-07890-5","volume":"51","author":"E Azoulay","year":"2025","unstructured":"Azoulay E, M\u00e9tais M, Lemiale V, et al. Outcomes in immunocompromised patients with acute hypoxemic respiratory failure treated by high-flow nasal oxygen. Intensive Care Med. 2025;51(4):731\u201341.","journal-title":"Intensive Care Med"},{"key":"854_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103300","volume":"85","author":"I Martin-Loeches","year":"2025","unstructured":"Martin-Loeches I, David S, P\u00e8ne F, et al. Advocating for the recognition of underlying immunosuppression in critical illness. EClinicalMedicine. 2025;85:103300.","journal-title":"EClinicalMedicine"},{"issue":"18","key":"854_CR64","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM200005043421801","volume":"342","author":"ARDS Network","year":"2000","unstructured":"Network ARDS, Brower RG, Matthay MA, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301\u20138.","journal-title":"N Engl J Med"},{"issue":"12","key":"854_CR65","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1005372","volume":"363","author":"L Papazian","year":"2010","unstructured":"Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107\u201316.","journal-title":"N Engl J Med"},{"issue":"21","key":"854_CR66","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1056\/NEJMoa1800385","volume":"378","author":"A Combes","year":"2018","unstructured":"Combes A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965\u201375.","journal-title":"N Engl J Med"},{"issue":"16","key":"854_CR67","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids\u2014new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711\u201323.","journal-title":"N Engl J Med"},{"issue":"12","key":"854_CR68","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1097\/CCM.0000000000002737","volume":"45","author":"D Annane","year":"2017","unstructured":"Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (circi) in critically ill patients (part I): Society of critical care medicine (sccm) and european society of intensive care medicine (esicm) 2017. Crit Care Med. 2017;45(12):2078\u201388.","journal-title":"Crit Care Med"},{"issue":"10","key":"854_CR69","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ncprheum0898","volume":"4","author":"C Stahn","year":"2008","unstructured":"Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008;4(10):525\u201333.","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"1-2","key":"854_CR70","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.mce.2007.05.019","volume":"275","author":"C Stahn","year":"2007","unstructured":"Stahn C, L\u00f6wenberg M, Hommes DW, et al. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol. 2007;275(1\u20132):71\u20138.","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"854_CR71","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1164\/rccm.200406-808OC","volume":"171","author":"M Confalonieri","year":"2005","unstructured":"Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171(3):242\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"854_CR72","doi-asserted-by":"publisher","first-page":"519","DOI":"10.7326\/M15-0715","volume":"163","author":"RA Siemieniuk","year":"2015","unstructured":"Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(7):519\u201328.","journal-title":"Ann Intern Med"},{"issue":"21","key":"854_CR73","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","volume":"388","author":"PF Dequin","year":"2023","unstructured":"Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;388(21):1931\u201341.","journal-title":"N Engl J Med"},{"issue":"22","key":"854_CR74","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2507100","volume":"393","author":"RK Lucinde","year":"2025","unstructured":"Lucinde RK, Gathuri H, Mwaniki P, et al. A pragmatic trial of glucocorticoids for community-acquired pneumonia. N Engl J Med. 2025;393(22):2187\u201397.","journal-title":"N Engl J Med"},{"issue":"4","key":"854_CR75","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00134-025-07861-w","volume":"51","author":"REMAP-CAP Investigators","year":"2025","unstructured":"Investigators REMAP-CAP, Angus DC. Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia\u202f: The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial. Intensive Care Med. 2025;51(4):665\u201380.","journal-title":"Intensive Care Med"},{"issue":"1","key":"854_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04613-4","volume":"27","author":"I Martin-Loeches","year":"2023","unstructured":"Martin-Loeches I, Nagavci B, Torres A. Final approval for corticosteroids in severe CAP? For sure, in septic shock. Crit Care. 2023;27(1):342.","journal-title":"Crit Care"},{"key":"854_CR77","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0346-2020","author":"I Martin-Loeches","year":"2021","unstructured":"Martin-Loeches I, Torres A. Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm? Eur Respir Rev. 2021. https:\/\/doi.org\/10.1183\/16000617.0346-2020.","journal-title":"Eur Respir Rev"},{"issue":"3","key":"854_CR78","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S2213-2600(24)00418-1","volume":"13","author":"LF Reyes","year":"2025","unstructured":"Reyes LF, Martin-Loeches I. Corticosteroids in community-acquired pneumonia: a step forward, but questions remain. Lancet Respir Med. 2025;13(3):191\u20133.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"854_CR79","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nri.2016.136","volume":"17","author":"MP Soares","year":"2017","unstructured":"Soares MP, Teixeira L, Moita LF. Disease tolerance and immunity in host protection against infection. Nat Rev Immunol. 2017;17(2):83\u201396.","journal-title":"Nat Rev Immunol"},{"key":"854_CR80","doi-asserted-by":"publisher","first-page":"1479804","DOI":"10.3389\/fphar.2024.1479804","volume":"15","author":"P Wang","year":"2024","unstructured":"Wang P, Wan J, You Q, et al. Association between various types of corticosteroids and mortality for severe community-acquired pneumonia in adults: a systematic review and network meta-analysis. Front Pharmacol. 2024;15:1479804.","journal-title":"Front Pharmacol"},{"key":"854_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13102386","author":"A Valsamaki","year":"2025","unstructured":"Valsamaki A, Vazgiourakis V, Mantzarlis K, et al. Immune dysregulation in sepsis. A narrative review for the clinicians. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13102386.","journal-title":"Biomedicines"},{"issue":"1","key":"854_CR82","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s40001-025-02487-6","volume":"30","author":"X Gu","year":"2025","unstructured":"Gu X, Yang P, Yu L, et al. Glucocorticoids can reduce mortality in patients with severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res. 2025;30(1):215.","journal-title":"Eur J Med Res"},{"key":"854_CR83","volume":"36","author":"JP Cidade","year":"2024","unstructured":"Cidade JP, Guerreiro G, P\u00f3voa P. A clinical guide to assess the immune response to sepsis: from bench to bedside. Crit Care Sci. 2024;36:e20240179en.","journal-title":"Crit Care Sci"},{"issue":"1","key":"854_CR84","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13613-017-0268-3","volume":"7","author":"I Martin-Loeches","year":"2017","unstructured":"Martin-Loeches I, Muriel-Bomb\u00edn A, Ferrer R, et al. The protective association of endogenous immunoglobulins against sepsis mortality is restricted to patients with moderate organ failure. Ann Intensive Care. 2017;7(1):44.","journal-title":"Ann Intensive Care"},{"issue":"4","key":"854_CR85","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00134-018-5143-7","volume":"44","author":"T Welte","year":"2018","unstructured":"Welte T, Dellinger RP, Ebelt H, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med. 2018;44(4):438\u201348.","journal-title":"Intensive Care Med"},{"issue":"4","key":"854_CR86","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(23)00330-2","volume":"12","author":"S Cajander","year":"2024","unstructured":"Cajander S, Kox M, Scicluna BP, et al. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine. Lancet Respir Med. 2024;12(4):305\u201322.","journal-title":"Lancet Respir Med"},{"issue":"52","key":"854_CR87","doi-asserted-by":"publisher","first-page":"E12353","DOI":"10.1073\/pnas.1809700115","volume":"115","author":"C Langelier","year":"2018","unstructured":"Langelier C, Kalantar KL, Moazed F, et al. Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults. Proc Natl Acad Sci U S A. 2018;115(52):E12353-e12362.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"854_CR88","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41467-018-03078-2","volume":"9","author":"TE Sweeney","year":"2018","unstructured":"Sweeney TE, Perumal TM, Henao R, et al. A community approach to mortality prediction in sepsis via gene expression analysis. Nat Commun. 2018;9(1):694.","journal-title":"Nat Commun"},{"issue":"13","key":"854_CR89","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2020.17022","volume":"324","author":"DC Angus","year":"2020","unstructured":"Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317\u201329.","journal-title":"JAMA"},{"issue":"7","key":"854_CR90","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1513\/AnnalsATS.202003-192SD","volume":"17","author":"DC Angus","year":"2020","unstructured":"Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (randomized embedded multifactorial adaptive platform for community-acquired pneumonia) study. rationale and design. Ann Am Thorac Soc. 2020;17(7):879\u201391.","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"854_CR91","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1164\/rccm.202401-0101CP","volume":"209","author":"P Practical","year":"2024","unstructured":"Practical P. TRAITS, INCEPT, and REMAP-CAP investigators, The rise of adaptive platform trials in critical care. Am J Respir Crit Care Med. 2024;209(5):491\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"346","key":"854_CR92","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf7165","volume":"8","author":"TE Sweeney","year":"2016","unstructured":"Sweeney TE, Wong HR, Khatri P. Robust classification of bacterial and viral infections via integrated host gene expression diagnostics. Sci Transl Med. 2016;8(346):346ra91.","journal-title":"Sci Transl Med"},{"issue":"1","key":"854_CR93","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13073-016-0326-8","volume":"8","author":"S Grumaz","year":"2016","unstructured":"Grumaz S, Stevens P, Grumaz C, et al. Next-generation sequencing diagnostics of bacteremia in septic patients. Genome Med. 2016;8(1):73.","journal-title":"Genome Med"},{"issue":"1","key":"854_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116949","volume":"10","author":"S Murthy","year":"2015","unstructured":"Murthy S, Leligdowicz A, Adhikari NK. Intensive care unit capacity in low-income countries: a systematic review. PLoS ONE. 2015;10(1):e0116949.","journal-title":"PLoS ONE"}],"container-title":["Journal of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40560-026-00854-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-026-00854-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-026-00854-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:02:55Z","timestamp":1772193775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40560-026-00854-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1186\/s40560-026-00854-x","relation":{},"ISSN":["2052-0492"],"issn-type":[{"value":"2052-0492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript is a narrative review based exclusively on previously published literature and does not involve human participants, patient data, or animal experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IML reports personal fees and\/or non-financial support from Thermofisher Scientific, bioM\u00e9rieux, MSD, Gilead Sciences, Mundipharma, and Pfizer, outside the submitted work. AA, DM, SF, PP, AR, and FR declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}